Table 2 Clinical characteristics of the study tumor samples
From: Vav2 protein overexpression marks and may predict the aggressive subtype of ductal carcinoma in situ
Characteristic | Status | IBC (%) | CIS (%) |
|---|---|---|---|
Tumor size | pT1 | 13.3 | Â |
pT2 | 65.3 | Â | |
pT3 | 19.4 | Â | |
pT4 | 1.0 | Â | |
No report | 1.0 | Â | |
Lymph node status | pN0 | 44.9 | Â |
pN1 | 20.4 | Â | |
pN2 | 19.4 | Â | |
pN3 | 8.2 | Â | |
pNx | 6.1 | Â | |
No report | 1.0 | Â | |
Grade (Nottingham score) | I | 2.0 | 4.2 |
II | 38.8 | 43.7 | |
III | 46.9 | 38.0 | |
No report | 12.2 | 14.1 | |
Estrogen Receptor | Negative | 33.7 | 32.4 |
Positive | 65.3 | 67.6 | |
No report | 1.0 | 0.0 | |
Progesterone Receptor | Negative | 43.9 | 39.4 |
Positive | 55.1 | 60.6 | |
No report | 1.0 | 0 | |
HER2/ErbB2/neu | Negative/ Equivocal | 81.6 | 69.0 |
Positive | 17.3 | 21.1 | |
No report | 1.0 | 9.9 |